MAIA Biotechnology, Inc.

Contributing Author

Recent Articles by MAIA Biotechnology, Inc.

9 hours	MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates MAIA +18.84% GlobeNewswire
13 hours	MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer MAIA +18.84% GlobeNewswire
14 hours	MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential MAIA +18.84% GlobeNewswire
Dec-10	MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach MAIA GlobeNewswire
Dec-01	MAIA Biotechnology Announces Open Market Purchases by CEO and Directors MAIA GlobeNewswire
Nov-21	MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 MAIA GlobeNewswire
Nov-20	MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation MAIA GlobeNewswire
Oct-27	MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics MAIA GlobeNewswire
Oct-23	MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA GlobeNewswire
Oct-13	MAIA Biotechnology Announces $736,600 Private Placement MAIA GlobeNewswire
Oct-07	MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets MAIA GlobeNewswire
Sep-29	MAIA Biotechnology Announces $2.25 Million Private Placement MAIA GlobeNewswire
Sep-24	MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent MAIA GlobeNewswire
Sep-11	MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer MAIA GlobeNewswire
Sep-05	MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer MAIA GlobeNewswire
Aug-27	MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells MAIA GlobeNewswire
Aug-13	MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy MAIA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.